Silo Pharma (NASDAQ: SILO) has reported encouraging preclinical outcomes for SP-26, its innovative extended-release ketamine implant designed to combat fibromyalgia. The study, conducted on minipigs, successfully met all its objectives, including assessments of safety, tolerability, and pharmacokinetics, without any implant-related adverse effects. Notably, the implant facilitated sustained ketamine release over a period of up to 22 days. According to CEO Eric Weisblum, these findings bolster the case for SP-26's progression as a next-generation, abuse-deterrent pain management solution.
SP-26 is engineered for subcutaneous administration, circumventing the dissociative side effects associated with intravenous ketamine. This feature positions SP-26 as a potentially safer alternative to opioid-based therapies, with the added prospect of becoming the first at-home injectable ketamine treatment for chronic pain. The development of SP-26 underscores Silo Pharma's commitment to addressing unmet needs in the realm of chronic pain and psychiatric disorders through innovative drug delivery systems and formulations.
The implications of SP-26's success extend beyond fibromyalgia, offering hope for individuals suffering from various chronic pain conditions and potentially reducing reliance on opioids, which are fraught with risks of addiction and overdose. Furthermore, this advancement highlights the growing role of psychedelic compounds in developing novel therapeutics, signaling a shift in how pain and psychiatric disorders may be treated in the future. For more details on the study, visit https://ibn.fm/APuat.
